AnaptysBio, Inc. - ROE
ANAB
Price:
$57.51
Market Cap:
$2.48B
AnaptysBio, Inc. is a biotechnology firm currently in the clinical development phase, dedicated to pioneering novel therapeutic agents aimed at treating inflammatory conditions and immuno-oncological diseases. The company's portfolio features several promising drug candidates. These include Imsidolimab, an antibody designed to block the interleukin-36 receptor (IL-36R), targeting diverse skin-related inflammatory disorders. Another key program is Rosnilimab, an anti-PD-1 agonist antibody, which works by enhancing PD-1 signaling to mitigate human inflammatory diseases driven by T-cells. Furthermore, ANB032, an anti-BTLA modulator antibody, addresses human inflammatory conditions linked to imb...[Read more]
Industry
Biotechnology
IPO Date
2017-01-26
Stock Exchange
NASDAQ
Ticker
ANAB
PE Ratio
[-56.38]
ROE
[442.91%]
Current Ratio
[7.58]
Dividend Yield
[0%]
Enterprise Value
[2.51B]
Dividend History
The ROE as of June 2026 (TTM) for AnaptysBio, Inc. (ANAB) is 442.91%
According to AnaptysBio, Inc.’s latest financial reports and current stock price. The company's current ROE is 442.91%. This represents a change of -818.54% compared to the average of -61.64% of the last 4 quarters.
AnaptysBio, Inc. (ANAB) Historical ROE (quarterly & annually)
How has ANAB ROE performed in the past?
The mean historical ROE of AnaptysBio, Inc. over the last ten years is -55.39%. The current 442.91% ROE has changed -899.63% with respect to the historical average. Over the past ten years (40 quarters), ANAB's ROE was at its highest in in the December 2025 quarter at 133.34%. The ROE was at its lowest in in the June 2024 quarter at -472.32%.
Average
-55.39%
Median
-20.12%
Minimum
-204.93%
Maximum
-5.02%
AnaptysBio, Inc. (ANAB) ROE by Quarter and Year
Discovering the peaks and valleys of AnaptysBio, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 278.14%
Maximum Annual ROE = -5.02%
Minimum Annual Increase = -82.65%
Minimum Annual ROE = -204.93%
| Year | ROE | Change |
|---|---|---|
| 2025 | -35.56% | -82.65% |
| 2024 | -204.93% | 10.35% |
| 2023 | -185.71% | 278.14% |
| 2022 | -49.11% | 202.87% |
| 2021 | -16.22% | 222.77% |
| 2020 | -5.02% | -79.10% |
| 2019 | -24.03% | 89.58% |
| 2018 | -12.68% | 29.67% |
| 2017 | -9.78% | -9.86% |
| 2016 | -10.85% | -15.04% |
AnaptysBio, Inc. (ANAB) Average ROE
How has ANAB ROE performed in the past?
The current ROE of AnaptysBio, Inc. (ANAB) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-142.07%
5-year avg
-98.31%
10-year avg
-55.39%
AnaptysBio, Inc. (ANAB) ROE vs. Peers
How is ANAB’s ROE compared to its peers?
AnaptysBio, Inc.’s ROE is greater than Xencor, Inc. (-28.77%), greater than Oculis Holding AG (-57.09%), less than Phathom Pharmaceuticals, Inc. (39.24%), greater than Mind Medicine (MindMed) Inc. (-102.48%), less than UroGen Pharma Ltd. (121.52%), greater than Nurix Therapeutics, Inc. (-64.21%), greater than BridgeBio Oncology Therapeutics Inc. (-61.49%), greater than Kodiak Sciences Inc. (-253.85%), greater than Dianthus Therapeutics, Inc. (-1.78%), greater than Taysha Gene Therapies, Inc. (-56.07%),
| Company | ROE | Market cap |
|---|---|---|
| -28.77% | $937.15M | |
| -57.09% | $641.44M | |
| 39.24% | $867.74M | |
| -102.48% | $1.56B | |
| 121.52% | $1.64B | |
| -64.21% | $1.52B | |
| -61.49% | $605.61M | |
| -253.85% | $1.91B | |
| -1.78% | $3.44B | |
| -56.07% | $1.61B |
Build a custom stock screener for AnaptysBio, Inc. (ANAB) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like AnaptysBio, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
AnaptysBio, Inc. (ANAB) and other stocks custom spreadsheet templates
The easiest way to analyze a company like AnaptysBio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is AnaptysBio, Inc.'s ROE?
How is the ROE calculated for AnaptysBio, Inc. (ANAB)?
What is the highest ROE for AnaptysBio, Inc. (ANAB)?
What is the 3-year average ROE for AnaptysBio, Inc. (ANAB)?
What is the 5-year average ROE for AnaptysBio, Inc. (ANAB)?
How does the current ROE for AnaptysBio, Inc. (ANAB) compare to its historical average?